Form 4: Avidity Biosciences CHRO Sells Shares

Avidity Biosciences' Chief Human Resources Officer, Teresa McCarthy, exercised options and sold 20,000 shares of common stock for a weighted-average price of $50.1529 per share.

Summary

• Teresa McCarthy, Chief Human Resources Officer of Avidity Biosciences, Inc. (RNA), reported an exercise of stock options and subsequent sale of common stock.
• On October 15, 2025, McCarthy acquired 20,000 shares of common stock by exercising stock options at a price of $22.34 per share.
• Immediately following the option exercise, McCarthy sold 20,000 shares of common stock at a weighted-average price of $50.1529 per share, with individual sales ranging from $48.20 to $51.19.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by McCarthy on April 11, 2025.
• After these transactions, McCarthy beneficially owns 97,130 shares of common stock directly.
• McCarthy also holds 65,000 stock options, which are fully vested and exercisable.

Sentiment

Score: 6

Explanation: The transaction represents a pre-planned exercise of options and sale of shares by a key executive, indicating personal financial planning rather than a reaction to new company developments. The executive realized a significant profit from the option exercise, which is a positive for the individual, but the sale itself can be viewed neutrally or slightly negatively by the market.

Positives

• The Chief Human Resources Officer realized a significant profit from the exercise of stock options and subsequent sale of shares, indicating personal financial success.
• The transaction was executed under a pre-established Rule 10b5-1 trading plan, suggesting a planned financial event rather than a reaction to new, adverse company information.

Negatives

• The sale of shares by a key executive, even if pre-planned, could be perceived negatively by some investors as a reduction in insider ownership.

Risks

• Insider selling, even under a 10b5-1 plan, can sometimes lead to negative market sentiment or speculation, potentially impacting the company's stock price.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may observe the insider selling and potentially react to the reduction in executive ownership, although the pre-planned nature mitigates immediate concerns.

Key Dates

Recommendation

The transaction is an exercise of stock options and subsequent sale of shares by a Chief Human Resources Officer, executed under a pre-established Rule 10b5-1 trading plan. While insider selling can sometimes be viewed negatively, the pre-planned nature of this transaction suggests personal financial management rather than a reflection of the company's immediate prospects. Investors should monitor broader market trends and company performance rather than reacting solely to this individual transaction.

Keywords

Avidity Biosciences, RNA, Teresa McCarthy, Form 4, Insider Trading, Stock Option Exercise, Share Sale, 10b5-1 Plan, Biotechnology, Pharmaceuticals